Efectos secundarios del implante subdérmico Implanon, como método anticonceptivo
Main Article Content
Abstract
«Implanon» is a modern contraceptive method, wich offers to users high contraceptive effectiveness until 99% in a period of 3 years; It's safe, comfortable and accessible; within the secondary effect described, such as the irregularities in the menstruation, the acne presence, you feel nauseous, headache; where the first one described, main chance due half of almost of the total of reasons to discontinue them.
Article Details
Section
How to Cite
References
http://es.wikipedia.org/wiki/M%C3%A9todo-anticonceptivo
Barbato WT, Charalambopoulos J. Tratado de la anticoncepción. Corpus. 1a. Ed. p. 33-41, 90-93, 117-118 y 221-4.
Norma Oficial Mexicana-005-SSA2-1993, de los Servicios de Planificación Familiar, modificada 21/junio/2004.
Upadhyay UD. Nuevas opciones de anticonceptivos. Population Reports. Serie M, No. 19, 70-2. Apr. 2005.
www.imss.gob.mx/cuadrobasico/medicamentos/ Dentall.aspx?clavegrupo=19
Rehan N, Inayatullah A, Chaudhary I. Norplant: Reasons for discontinuation and sicle-effects. European Journal of Contraception and Reproductive Health Care 2000; 5(2): 113-18.
Croxatto HB. Progestim implants. Steroids 2000; 65(10-11): 681-5.
Affandi B. Long-acting progestogens. Best Practice and Research. Clinical Obstetrics and Gynaecology 2002; 16(2): 169-79.
Cravioto MDC, Alvarado G, Canto de Cetina T, Bassol S, Oropeza G, Santos-Yung R, Valencia J, Palma Y, et al. Multicenter Comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant and Norplant-II. Contraception 1997; 55(6): 359-67.
Affandi B, Korver T, Geurts TB, Coelingh Benning HJ. A pilot efficacy stidy with a single-rod contraceptive implant (Implanon) in 200 Indonesian women treated for 4 years. Contreception 1999; 59(3): 167-76.
Sivin I. Risks and benefits, advantages and disadvantages or levonogestrel-releasing contraceptive implants. Drug Safety 2003; 26(5): 303-35.
Croxatto HB. Progestin implants. Steroids 2000; 65(10-11): 681-5.
World Hearth Organization (WHO). Contraceptive implants come of age. Progres in Reproductive Health Research 2003; (61): 2-5.
Coutinho EM, Desouza JC, Athayde C, Barbosa I, cols. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant. Contraception 1996; 53(2): 121-5.
Riney S, Oshea B. Etonogestrel implant as a contraceptive choice; patient acceptability and adverse effect profile in a general practice setting. Irish Medical Journal 2009; 102(1): 24-5.
Glasier A. Implantable contraceptive for women: Effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception 2002; 65(1): 29-37.
Kang W, Tang KH. Implant contraception in Singaporean women: one decade of experience in KK Women's and Children's Hospital. Singapore Medical Journal 2004; 45(10): 482-6.
Mutihir JT, Daru PH. Implanon sub-dermal implants: a 10month review of acceptability in Jos, North-Central Nigeria. Nigerian Journal of Clinical Practice 2008; 11(4): 320-3.
Rodríguez BMR, Lara RRJ, De la Jara DJ, Torres RA, Ahued AJR. Norplant: una experiencian de tres años del Instituto Nacional de Perinatología en México. Ginecología y Obstetricia de México 1999; 67(2): 385-9.
Brache V, Faundes A, Alvarez F, An Cochon L. Nonmenstrual adverse events during use of implantable contraceptives for women: Data from clinical trials. Contraception 2002; 65(1): 63-74.
Meckstroth KR, Darney PD. Implant contraception. Seminars in Reproductive Medicine 2001; 19(4): 339-54.
www.facmed.unam.mx/bmnd/plm.2k8/src/prods/tablas/*.jpg
Plan Nacional de Salud 2007-2012. Cap. III. México: p. 69-71.
Constitución Política de los Estados Unidos Mexicanos, Edit. Fringe; 2009, p. 8
Consejo Nacional de Población. Programa Nacional de Población 2007-2012. México: p. 32-5.
Seminars in reproductive medicine 2001; 19(4): 339-54.